| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 51 | 2022 | 92 | 24.610 |
Why?
|
| Skin | 20 | 2022 | 303 | 6.720 |
Why?
|
| Melanocytes | 15 | 2022 | 65 | 5.610 |
Why?
|
| Hypopigmentation | 7 | 2022 | 10 | 4.250 |
Why?
|
| Skin Pigmentation | 7 | 2021 | 31 | 3.040 |
Why?
|
| Alopecia Areata | 6 | 2018 | 9 | 3.010 |
Why?
|
| Autoimmunity | 10 | 2021 | 208 | 2.930 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2021 | 631 | 2.810 |
Why?
|
| Immunotherapy | 4 | 2020 | 202 | 2.510 |
Why?
|
| Autoimmune Diseases | 6 | 2021 | 192 | 2.180 |
Why?
|
| Chemokine CXCL10 | 10 | 2022 | 49 | 1.920 |
Why?
|
| Interferon-gamma | 10 | 2022 | 537 | 1.890 |
Why?
|
| T-Lymphocytes | 5 | 2020 | 903 | 1.850 |
Why?
|
| Janus Kinase Inhibitors | 3 | 2020 | 10 | 1.840 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2022 | 163 | 1.800 |
Why?
|
| Immunologic Memory | 6 | 2021 | 322 | 1.750 |
Why?
|
| Melanoma, Experimental | 2 | 2021 | 43 | 1.680 |
Why?
|
| Pyrazoles | 5 | 2022 | 60 | 1.670 |
Why?
|
| Skin Diseases | 4 | 2022 | 69 | 1.650 |
Why?
|
| Receptors, CXCR3 | 4 | 2020 | 28 | 1.630 |
Why?
|
| Chemokines | 3 | 2021 | 90 | 1.540 |
Why?
|
| Disease Models, Animal | 11 | 2022 | 1799 | 1.380 |
Why?
|
| Humans | 63 | 2022 | 48594 | 1.340 |
Why?
|
| Animals | 33 | 2022 | 17856 | 1.300 |
Why?
|
| Simvastatin | 2 | 2017 | 21 | 1.200 |
Why?
|
| Chemokine CXCL9 | 5 | 2020 | 20 | 1.200 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 694 | 1.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2017 | 165 | 1.150 |
Why?
|
| Signal Transduction | 8 | 2020 | 2730 | 1.090 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2021 | 13 | 1.040 |
Why?
|
| Dermatology | 3 | 2019 | 45 | 1.030 |
Why?
|
| Mice | 21 | 2022 | 9050 | 1.000 |
Why?
|
| Immunity, Innate | 8 | 2021 | 688 | 0.940 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 2021 | 5 | 0.900 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 7 | 0.880 |
Why?
|
| Receptors, CCR5 | 1 | 2021 | 51 | 0.870 |
Why?
|
| Biological Products | 1 | 2022 | 63 | 0.860 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 46 | 0.860 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 28 | 0.860 |
Why?
|
| Cross-Priming | 1 | 2020 | 17 | 0.830 |
Why?
|
| Hair Dyes | 2 | 2017 | 5 | 0.810 |
Why?
|
| Epidermis | 2 | 2018 | 35 | 0.810 |
Why?
|
| Pyrimidines | 6 | 2021 | 104 | 0.800 |
Why?
|
| Immunity, Cellular | 4 | 2019 | 179 | 0.790 |
Why?
|
| Interferon Type I | 2 | 2020 | 157 | 0.790 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 2901 | 0.760 |
Why?
|
| Efficiency | 1 | 2019 | 41 | 0.740 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1130 | 0.730 |
Why?
|
| Interleukin-15 | 1 | 2018 | 15 | 0.720 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 39 | 0.720 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 230 | 0.700 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 139 | 0.700 |
Why?
|
| Melanoma | 1 | 2021 | 283 | 0.700 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 182 | 0.680 |
Why?
|
| Skin Lightening Preparations | 1 | 2017 | 3 | 0.660 |
Why?
|
| Blister | 1 | 2017 | 11 | 0.660 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 256 | 0.660 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 73 | 0.650 |
Why?
|
| Stress, Physiological | 2 | 2016 | 177 | 0.630 |
Why?
|
| Bullying | 1 | 2016 | 9 | 0.620 |
Why?
|
| Phenols | 1 | 2017 | 61 | 0.620 |
Why?
|
| Nitriles | 4 | 2021 | 52 | 0.610 |
Why?
|
| Antibodies | 1 | 2017 | 161 | 0.610 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 357 | 0.600 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 1125 | 0.590 |
Why?
|
| Melanins | 1 | 2015 | 16 | 0.590 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.580 |
Why?
|
| Organ Specificity | 1 | 2016 | 175 | 0.580 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 309 | 0.570 |
Why?
|
| Ultraviolet Therapy | 3 | 2022 | 8 | 0.570 |
Why?
|
| Genetic Vectors | 1 | 2020 | 680 | 0.570 |
Why?
|
| Hair | 1 | 2015 | 72 | 0.570 |
Why?
|
| Male | 18 | 2021 | 23091 | 0.560 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2021 | 573 | 0.540 |
Why?
|
| Psoriasis | 2 | 2016 | 46 | 0.540 |
Why?
|
| Adult | 11 | 2021 | 13144 | 0.490 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 1154 | 0.470 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 2 | 0.460 |
Why?
|
| Ureteral Obstruction | 1 | 2021 | 9 | 0.450 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 285 | 0.440 |
Why?
|
| Adaptive Immunity | 3 | 2017 | 84 | 0.420 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 178 | 0.410 |
Why?
|
| Dermatitis, Contact | 1 | 2010 | 11 | 0.410 |
Why?
|
| Keratinocytes | 2 | 2022 | 49 | 0.390 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 151 | 0.390 |
Why?
|
| Receptors, CCR6 | 2 | 2022 | 10 | 0.390 |
Why?
|
| Thrombosis | 1 | 2021 | 188 | 0.380 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 546 | 0.380 |
Why?
|
| Female | 15 | 2021 | 26148 | 0.380 |
Why?
|
| Double-Blind Method | 3 | 2021 | 545 | 0.380 |
Why?
|
| Young Adult | 4 | 2021 | 3621 | 0.380 |
Why?
|
| Apoptosis | 1 | 2015 | 1026 | 0.380 |
Why?
|
| Exophiala | 1 | 2008 | 1 | 0.380 |
Why?
|
| Leg Dermatoses | 1 | 2008 | 3 | 0.370 |
Why?
|
| Biomarkers | 3 | 2020 | 962 | 0.370 |
Why?
|
| Clonal Anergy | 2 | 2009 | 26 | 0.370 |
Why?
|
| Dermatomycoses | 1 | 2008 | 11 | 0.370 |
Why?
|
| Middle Aged | 8 | 2021 | 13423 | 0.370 |
Why?
|
| Adolescent | 4 | 2021 | 5306 | 0.350 |
Why?
|
| Oxidative Stress | 2 | 2021 | 245 | 0.330 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2020 | 3 | 0.330 |
Why?
|
| Phenotype | 3 | 2021 | 1007 | 0.320 |
Why?
|
| Case-Control Studies | 2 | 2020 | 885 | 0.300 |
Why?
|
| STAT1 Transcription Factor | 2 | 2016 | 31 | 0.300 |
Why?
|
| Consensus | 3 | 2021 | 114 | 0.290 |
Why?
|
| Administration, Oral | 2 | 2017 | 292 | 0.290 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 730 | 0.280 |
Why?
|
| Interleukin-17 | 2 | 2017 | 71 | 0.280 |
Why?
|
| Treatment Outcome | 5 | 2022 | 3803 | 0.270 |
Why?
|
| Inflammation | 3 | 2016 | 941 | 0.260 |
Why?
|
| Skin Physiological Phenomena | 2 | 2014 | 14 | 0.260 |
Why?
|
| Cytokines | 2 | 2020 | 820 | 0.250 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 55 | 0.230 |
Why?
|
| Tissue Distribution | 1 | 2022 | 237 | 0.230 |
Why?
|
| Cell Differentiation | 3 | 2016 | 1232 | 0.220 |
Why?
|
| Phototherapy | 2 | 2022 | 21 | 0.220 |
Why?
|
| Gene Ontology | 1 | 2021 | 32 | 0.220 |
Why?
|
| Republic of Korea | 1 | 2021 | 21 | 0.220 |
Why?
|
| CD28 Antigens | 2 | 2015 | 39 | 0.220 |
Why?
|
| Autoantigens | 3 | 2021 | 124 | 0.220 |
Why?
|
| Piperidines | 2 | 2020 | 36 | 0.220 |
Why?
|
| Dermatologic Agents | 1 | 2021 | 16 | 0.220 |
Why?
|
| Epidemiologic Studies | 1 | 2021 | 40 | 0.210 |
Why?
|
| Ointments | 1 | 2020 | 5 | 0.210 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 69 | 0.210 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 34 | 0.210 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 107 | 0.210 |
Why?
|
| Skin Cream | 1 | 2020 | 1 | 0.210 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 307 | 0.210 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 45 | 0.210 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 45 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2021 | 94 | 0.200 |
Why?
|
| Bleomycin | 1 | 2020 | 16 | 0.200 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 6 | 0.200 |
Why?
|
| Genetic Testing | 1 | 2021 | 113 | 0.200 |
Why?
|
| Vaccinia virus | 1 | 2020 | 99 | 0.200 |
Why?
|
| Photography | 1 | 2019 | 33 | 0.190 |
Why?
|
| Fibrosis | 1 | 2020 | 99 | 0.190 |
Why?
|
| Cell Movement | 2 | 2019 | 393 | 0.190 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 144 | 0.190 |
Why?
|
| Dermatologists | 1 | 2019 | 8 | 0.190 |
Why?
|
| Ligands | 1 | 2020 | 396 | 0.190 |
Why?
|
| Cell Death | 2 | 2018 | 241 | 0.190 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 40 | 0.190 |
Why?
|
| Stem Cell Factor | 1 | 2018 | 24 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2004 | 1439 | 0.180 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2018 | 2 | 0.180 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 63 | 0.180 |
Why?
|
| Aged | 4 | 2021 | 10797 | 0.180 |
Why?
|
| Disease Management | 1 | 2020 | 181 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 596 | 0.180 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 188 | 0.180 |
Why?
|
| Fas Ligand Protein | 1 | 2018 | 39 | 0.180 |
Why?
|
| Pigmentation | 2 | 2015 | 21 | 0.180 |
Why?
|
| Early Growth Response Protein 2 | 2 | 2010 | 8 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 137 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 476 | 0.180 |
Why?
|
| Foundations | 1 | 2018 | 6 | 0.170 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 5 | 0.170 |
Why?
|
| Dendritic Cells | 1 | 2021 | 493 | 0.170 |
Why?
|
| Global Health | 1 | 2019 | 136 | 0.170 |
Why?
|
| Swine | 1 | 2018 | 298 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2014 | 888 | 0.170 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 92 | 0.170 |
Why?
|
| Phenylenediamines | 1 | 2017 | 4 | 0.170 |
Why?
|
| Catechols | 1 | 2017 | 5 | 0.170 |
Why?
|
| Hydroquinones | 1 | 2017 | 8 | 0.170 |
Why?
|
| Pyrroles | 1 | 2017 | 49 | 0.170 |
Why?
|
| Chemokine CXCL11 | 1 | 2017 | 4 | 0.170 |
Why?
|
| Self Tolerance | 1 | 2017 | 16 | 0.160 |
Why?
|
| Suction | 1 | 2017 | 24 | 0.160 |
Why?
|
| Body Surface Area | 1 | 2017 | 14 | 0.160 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 194 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2018 | 307 | 0.160 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 34 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2016 | 40 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2017 | 178 | 0.160 |
Why?
|
| Regeneration | 1 | 2017 | 92 | 0.160 |
Why?
|
| Flow Cytometry | 1 | 2018 | 659 | 0.160 |
Why?
|
| ROC Curve | 1 | 2017 | 226 | 0.150 |
Why?
|
| Immune Complex Diseases | 1 | 2016 | 2 | 0.150 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 13 | 0.150 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 47 | 0.150 |
Why?
|
| Dermatitis | 1 | 2016 | 19 | 0.150 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 47 | 0.150 |
Why?
|
| Child | 2 | 2019 | 3660 | 0.150 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 219 | 0.150 |
Why?
|
| Risk | 1 | 2016 | 364 | 0.150 |
Why?
|
| Quality of Life | 2 | 2018 | 704 | 0.140 |
Why?
|
| Antioxidants | 1 | 2017 | 205 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 4210 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 2015 | 94 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2015 | 112 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 127 | 0.140 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 648 | 0.140 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 40 | 0.140 |
Why?
|
| Prospective Studies | 1 | 2021 | 2469 | 0.130 |
Why?
|
| DNA | 1 | 2018 | 700 | 0.130 |
Why?
|
| Monocytes | 1 | 2016 | 335 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2019 | 1678 | 0.130 |
Why?
|
| Immunity | 1 | 2014 | 89 | 0.130 |
Why?
|
| Scalp | 1 | 2013 | 26 | 0.130 |
Why?
|
| Wound Healing | 1 | 2014 | 152 | 0.130 |
Why?
|
| High Mobility Group Proteins | 1 | 2013 | 20 | 0.130 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 33 | 0.130 |
Why?
|
| Neutrophils | 1 | 2016 | 337 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2019 | 1572 | 0.120 |
Why?
|
| Renal Circulation | 1 | 2021 | 11 | 0.110 |
Why?
|
| Intestines | 1 | 2013 | 136 | 0.110 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 142 | 0.110 |
Why?
|
| Methylation | 1 | 2021 | 121 | 0.110 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 68 | 0.110 |
Why?
|
| Toxoplasmosis | 1 | 2010 | 12 | 0.100 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2010 | 76 | 0.100 |
Why?
|
| RNA, Small Interfering | 3 | 2022 | 796 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2022 | 300 | 0.090 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2008 | 1 | 0.090 |
Why?
|
| Itraconazole | 1 | 2008 | 7 | 0.090 |
Why?
|
| DNA, Fungal | 1 | 2008 | 60 | 0.090 |
Why?
|
| Culture Media | 1 | 2008 | 75 | 0.090 |
Why?
|
| Interleukin-2 | 2 | 2009 | 158 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 142 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 156 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2008 | 98 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 374 | 0.080 |
Why?
|
| Zinc Fingers | 2 | 2004 | 93 | 0.080 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1996 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1315 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2018 | 1893 | 0.070 |
Why?
|
| Antigens, Ly | 2 | 2016 | 43 | 0.070 |
Why?
|
| CD3 Complex | 1 | 2004 | 67 | 0.070 |
Why?
|
| Clone Cells | 1 | 2004 | 106 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 69 | 0.070 |
Why?
|
| Cell Line | 2 | 2009 | 1975 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2004 | 365 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 263 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 849 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2004 | 823 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2004 | 357 | 0.060 |
Why?
|
| Emollients | 1 | 2021 | 5 | 0.060 |
Why?
|
| Lighting | 1 | 2019 | 14 | 0.050 |
Why?
|
| Reference Standards | 1 | 2019 | 62 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2063 | 0.050 |
Why?
|
| International Cooperation | 1 | 2019 | 83 | 0.050 |
Why?
|
| Internationality | 1 | 2019 | 37 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 129 | 0.050 |
Why?
|
| Observer Variation | 1 | 2019 | 175 | 0.050 |
Why?
|
| Immune System | 1 | 2020 | 124 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 329 | 0.040 |
Why?
|
| RNA Interference | 1 | 2022 | 602 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2018 | 107 | 0.040 |
Why?
|
| Janus Kinase 3 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 5 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2000 | 330 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2018 | 153 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2018 | 152 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 200 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1534 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 75 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 383 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 75 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1443 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 583 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2000 | 578 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 996 | 0.040 |
Why?
|
| Endotoxins | 1 | 2016 | 70 | 0.040 |
Why?
|
| Mast Cells | 1 | 2016 | 36 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 52 | 0.040 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 15 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 897 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 163 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 430 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 75 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 121 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 809 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 12 | 0.030 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 7 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 331 | 0.030 |
Why?
|
| Interleukins | 1 | 2013 | 72 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 579 | 0.030 |
Why?
|
| Rheology | 1 | 2013 | 55 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 68 | 0.030 |
Why?
|
| Base Sequence | 2 | 2009 | 1318 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 884 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 222 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 211 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 135 | 0.030 |
Why?
|
| Toxoplasma | 1 | 2010 | 25 | 0.030 |
Why?
|
| Macrophages | 1 | 2016 | 916 | 0.020 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2010 | 125 | 0.020 |
Why?
|
| Columbidae | 1 | 2009 | 11 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2009 | 25 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 63 | 0.020 |
Why?
|
| Antigens | 1 | 2009 | 136 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 296 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2009 | 184 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 4410 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 650 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 4208 | 0.020 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2000 | 11 | 0.010 |
Why?
|
| Snail Family Transcription Factors | 1 | 2000 | 25 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2000 | 24 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2000 | 26 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 123 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 215 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2000 | 65 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2000 | 177 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2000 | 169 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 195 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 324 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 267 | 0.010 |
Why?
|
| Binding Sites | 1 | 2000 | 859 | 0.010 |
Why?
|
| Chromatin | 1 | 2000 | 557 | 0.010 |
Why?
|